Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibeshih Belachew

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Multiple Sclerosis and Related Disorders|March 12, 2017
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypothesesGavin Giovannoni, Gary Cutter, Maria Pia Sormani, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L Hauser, Amit Bar-Or, Giancarlo Comi, et al.
Journal of Neuromuscular Diseases|July 12, 2024
Smartphone-Based Assessment of Mobility and Manual Dexterity in Adult People with Spinal Muscular AtrophyEduardo Arteaga-Bracho, Gautier Cosne, Christoph Kanzler, et al.
JAMA Network Open|February 12, 2024
Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging AbnormalitiesDiana M Sima, Thanh Vân Phan, Simon Van Eyndhoven, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Clinical Neurology and Neurosurgery|December 11, 2012
Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the youngIsabel De Brabander, Laetitia Yperzeele, Chantal Ceuterick-De Groote, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trialPeter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, et al.
JMIR Formative Research|November 8, 2024
Sensor-Derived Measures of Motor and Cognitive Functions in People With Multiple Sclerosis Using Unsupervised Smartphone-Based Assessments: Proof-of-Concept StudyMatthew Scaramozza, Aurélie Ruet, Patrizia A Chiesa, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
Nature Medicine|March 4, 2025
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairmentPaul Monroe Butler, Jenny Yang, Roland Brown, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis and Related Disorders|March 12, 2017
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypothesesGavin Giovannoni, Gary Cutter, Maria Pia Sormani, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L Hauser, Amit Bar-Or, Giancarlo Comi, et al.
Journal of Neuromuscular Diseases|July 12, 2024
Smartphone-Based Assessment of Mobility and Manual Dexterity in Adult People with Spinal Muscular AtrophyEduardo Arteaga-Bracho, Gautier Cosne, Christoph Kanzler, et al.
JAMA Network Open|February 12, 2024
Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging AbnormalitiesDiana M Sima, Thanh Vân Phan, Simon Van Eyndhoven, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Clinical Neurology and Neurosurgery|December 11, 2012
Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the youngIsabel De Brabander, Laetitia Yperzeele, Chantal Ceuterick-De Groote, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trialPeter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, et al.
JMIR Formative Research|November 8, 2024
Sensor-Derived Measures of Motor and Cognitive Functions in People With Multiple Sclerosis Using Unsupervised Smartphone-Based Assessments: Proof-of-Concept StudyMatthew Scaramozza, Aurélie Ruet, Patrizia A Chiesa, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
Nature Medicine|March 4, 2025
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairmentPaul Monroe Butler, Jenny Yang, Roland Brown, et al.
Pageof 9